Premature Treatment Discontinuation in HIV/HCV-Coinfected Patients Receiving Pegylated Interferon plus Weight-Based Ribavirin

Authors:

Abstract
Background: Chronic hepatitis C therapy in HIV patients is often penalized by more frequent premature treatment discontinuations. It is unclear what the relative contribution of more adverse events and/or early virological failures are. Methods: PRESCO was a prospective, multicentre, comparative trial, in which 389 HIV/HCV-coinfected patients with CD4 + T-cell counts >300 cells/ml and elevated aminotransferases received pegylated interferon-α2a (peg IFN-α2a) 180 mg per week plus ribavirin (RBV) 1,000–1,200 mg daily. Patients with HCV genotypes 1 or 4 were treated for 48 or 72 weeks while HCV genotypes 2 or 3 carriers were treated for 24 or 48 weeks. Use of didanosine was not allowed. Results: Sustained virological response (SVR) was achieved by 193 (49.6%), and was significantly greater in HCV-2/3 than in HCV-1/4 patients (72.4% versus 35%; P300 cells/ml most probably explains the lower and different spectrum of serious adverse events in PRESCO compared with prior trials conducted in coinfected patients.

This publication has 25 references indexed in Scilit: